Travere Therapeutics Reports Second Quarter 2022 Financial Results
August 04, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application...
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
May 16, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Travere Therapeutics Reports First Quarter 2022 Financial Results
May 05, 2022 16:01 ET
|
Travere Therapeutics, Inc.
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
April 20, 2022 16:30 ET
|
Travere Therapeutics, Inc.
Laura Clague to step-down as CFO in August 2022 and retire in 2023 Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in...
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
March 01, 2021 16:01 ET
|
Travere Therapeutics, Inc.
Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint Preparations underway for meetings with regulatory agencies in first half of 2021 to discuss...
Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
February 25, 2021 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare...
Travere Therapeutics to Present at Upcoming Investor Conferences
February 22, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
January 12, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
Travere Therapeutics Provides Corporate Update and 2021 Outlook
January 11, 2021 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
December 01, 2020 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...